|
Principal
Applicant
|
Title
of Project
|
Funding
Source and Program
|
Years
of Tenure
|
|
G. Batist
|
Optimizing Gene
Targeted Pharmacotherapy
|
National Science
and Engineering Research council
|
1995-1999
|
|
G. Batist
|
Environmental
Chemical Breast Carcinogens
|
Canadian Breast
Cancer Research Foundation
|
1996-1997
|
|
G. Batist
|
Role of Glutathione
in cancer treatment and prevention
|
NCIC
|
1997-2000
|
|
L. Panasci (PI)
|
Phase I study
of SarCNU
|
National Institutes
of Health USA
|
1998
|
|
G. Batist
|
Gene Targeted
pharmacotherapy
|
NCIC Canadian
Breast Cancer Research Initiative
|
1998-2001
|
|
W, Foulkes (PI),
M.Aloui-Jamali,
G. Batist
|
The cellular
and molecular basis of squamous cell carcinoma of the head and neck
in those with low exposure to tobacco and alcohol
|
NCIC
|
1999-2002
|
|
M.Aloui-Jamali,
G. Batist
|
Studies of the
effects of EGFr Kinase inhibitors on individual heterodimers of
the Her receptor family proteins
|
AstrZeneca (US)
|
|
|
G. Batist
|
Mechanisms of
glutathione regulation in hepatocarcinogenesis
|
Canadian Institutes
for Health Research
|
2001-2004
|
|
G. Batist
|
Regulation of
Connexin 43 in cancer prevention and therapy
|
NCIC Canadian
Breast Cancer Research Initiative
|
2001-2004
|
|
Scientific Director:
G. Batist
|
Montreal Center
for Experimental Therapeutics in Cancer
|
Canadian Fund
for Innovation /FRSQ
|
|
